Here’s why 23-year-old Laura Deming is betting $22M on anti-aging R&D
An MIT student at 14, a drop-out at 16 and an entrepreneur running her own small biotech venture fund at 17, Laura Deming is not your typical venture exec. Now, at 23, she’s raised a $22 million fund — her second for the Longevity Fund — that will look to invest in more companies like Unity Biotechnology which are looking to advance new anti-aging drugs.
Anti-aging is just now coming into vogue, as Unity Biotechnology’s recent $151 million B round indicates. But Deming got started long before anti-aging gained some traction with traditional VCs. Now, as the field gains steam, she plans on building on her bets.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.